期刊文献+

变应性鼻炎的药物治疗(一):治疗方案 被引量:43

下载PDF
导出
摘要 本文重点介绍制定变应性鼻炎(allergicrhinitis,AR)药物治疗方案的相关问题。AR是由变应原激发、由IgE介导的鼻部炎性疾病,从症状的持续时间和严重程度两个方面可分为四个亚型,依次为:轻度间歇性AR、中重度间歇性AR、轻度持续性AR和中重度持续性AR。制订AR药物治疗方案的前提是在确诊AR的基础上进一步分型,然后据此分别采用相应的治疗方案。根据治疗方案选择适当的药物,主要应考虑药物的疗效和可能产生的(局部和全身)副作用(安全性)。AR药物治疗体系中所涉及的药物种类并不复杂,鼻用皮质类固醇和(口服或鼻用)抗组胺药在其中占核心地位。由于儿童、孕妇和老年患者对药物的安全性有更严格的要求,因而被列入特殊关注的群体,在AR的药物治疗方面也各有特点。
出处 《中国耳鼻咽喉头颈外科》 北大核心 2006年第1期62-66,共5页 Chinese Archives of Otolaryngology-Head and Neck Surgery
基金 科技部"十五"国家科技攻关计划课题 变应性鼻炎综合诊治研究(2004BA720A19-01)
  • 相关文献

参考文献27

  • 1张罗,韩德民.变应性鼻炎治疗的进展[J].中华耳鼻咽喉头颈外科杂志,2005,40(3):230-232. 被引量:86
  • 2[4]Bousquet J,Van Cauwenberge P,Khaltaev N,et al.Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol,2001,108 (5 Suppl):S147-334.
  • 3[5]Gelfand EW.Pediatric allergic rhinitis:factors affecting treatment choice.Ear Nose Throat J,2005,84:163-168.
  • 4[6]Demoly P,Allaert FA,Lecasble M,et al.Validation of the classification of ARIA (allergic rhinitis and its impact on asthma).Allergy,2003,58:672-675.
  • 5[7]Simons FE,Simons KJ.The pharmacology and use of H1-receptor-antagonist drugs.N Engl J Med,1994,330:1663-1670.
  • 6张罗,韩德民,顾之燕.抗组胺药物 H1 受体拮抗剂的临床药理学(一):组胺、组胺受体和抗组胺药物[J].中国耳鼻咽喉头颈外科,2005,12(1):61-64. 被引量:33
  • 7[9]van Drunen C,Meltzer EO,Bachert C,et al.Nasal allergies and beyond:a clinical review of the pharmacology,efficacy,and safety of mometasone furoate.Allergy,2005,60 Suppl 80:5-19.
  • 8[10]Casale TB,Blaiss MS,Gelfand E,et al.First do no harm:managing antihistamine impairment in patients with allergic rhinitis.J Ailery Clin Immunol,2003,111:S835-S842.
  • 9[11]Bachert C,Bousquet J,Canonica GW,et al.Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis.J Allergy Clin Immunol,2004,114:838-844.
  • 10[12]Verster JC,Volkerts ER.Antihistamines and driving ability:evidence from on-the-road driving studies during normal traffic.Ann Allergy Asthma Immunol,2004,92:294-303.

二级参考文献136

  • 1Bousquet J,Van Cauwenberge P, Khaltaev N,et al.Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol,2001, 108(5 Suppl):S 147-334.
  • 2Marone G,Granata F,Spadaro G,et al.The histamine-cytokine network in allergic inflammation.J Allergy Clin Immunol,2003, 112 (4 Suppl):S83-88.
  • 3MacGlashan D Jr. Histamine:A mediator of inflammation.J Allergy Clin Immunol,2003, 112 (4 Suppl): S53-59.
  • 4Holt PG,Macaubas C,Stumbles PA,et al.The role of allergy in the development of asthma. Nature, 1999, 402 (6760 Suppl):B12-17.
  • 5Skoner DP.Allergic rhinitis:definition,epidemiology,pathophysiology, detection, and diagnosis.J Allergy Clin Immunol,2001,108 (1 Suppl): S2-8.
  • 6Mygind N.Sensitization,in Nasal Allergy, N Mygind,Editor, 1979,Blackwell Scientific Publications, 106-115.
  • 7Verster JC,Volkerts ER.Antihistamines and driving ability:evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol,2004, 92: 294-303.
  • 8Simons FE,Simons KJ.The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med,1994, 330: 1663-1670.
  • 9Berger WE,White MV,Rhinitis Study Group. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to Ioratadine.Ann Allergy Asthma Immunol,2003, 91: 205-211.
  • 10Hamasaki Y, Shafigeh M,Yamamoto S,et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol, 1996,76: 469-475.

共引文献205

同被引文献471

引证文献43

二级引证文献222

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部